Zantacs generic drugs will cost $30 a month in Australia, while a $15 a month increase in the price of its patented medicines will see prices rise to $100 a month.
The price increase will come into effect on January 1, 2017.
Zantac said the increase will see its generic drugs rise to around $300 a month, while its patented drug prices will rise to about $140 a month at the moment.
The generic drugs for the price increase include: Drugs that treat a range of conditions, including: Cancer treatments, Pain relievers, Anesthetics, Mood stabilisers and anti-depressants.
Drug costs have increased in the last few years, with many drugs going to the lowest-cost manufacturers.ZANTAC has been in negotiations with the Australian Government over its prescription drug pricing, with talks expected to begin soon.
The Government’s Pharmaceutical Pricing Review Panel has recommended that prices increase to $300 per month from $100 per month.
Zants chief executive Michael Fennell told the ABC last month that the increase was a “reasonable cost”.
Zantacs new drug, Bialan, will be available for $30 more than it would be in the United States, where it was introduced in 2011.
Zandag has also increased the price for its generic drug, Vioxx, to $70 a month from the current $45 a month and will be sold at the same prices as its patented drugs.
Zanti has also raised the price on the same generic drug.
Zanti’s drugs include:Anesthetisers, painkillers, anti-inflammatory medicines, antihistamines, pain killers and antibiotics.
Drug costs in Australia rose by 5.6 per cent last year, with the cost of drugs ranging from $25 a month to $50 a month compared with the previous year, according to data from the Pharmaceutical Pricing Advisory Committee.
Dr Paul Kooiman, CEO of the Australian Pharmaceutical Pricing Association, said the pharmaceutical industry was facing a “historic” situation and said there were many barriers to reaching a deal with the Government over price rises.
“In the last three years there has been a series of measures taken to drive down drug prices, particularly in the private sector, including measures such as a reduction in the number of patents and a reduction of the number and price of generic drugs,” Dr Kooisman said.
“And this has led to a situation where there are so many barriers that we cannot get there and it is not a sustainable situation.”
Zantacl chief executive Peter McEwen said the government was not going to go to war over price increases.
“The Australian Government is a great partner to us, we are a great customer, we provide the best drugs for our patients,” he said.
“We do not want to be seen as an opponent of pharmaceuticals.”
Zante is the only company that is the sole Australian company to have a patent on its drug, and it has the largest portfolio of generics in the world, including a significant range of drugs for diabetes, asthma, depression, HIV and heart disease.